# US 2025/0095777 A1 · Size-tagged preferred ends and orientation-aware analysis for measuring properties of cell-free mixtures

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0095777 A1
- Document ID: US20250095777A1
- Status: Published application
- Kind: A1
- Application number: 18/661,452
- Filed: 2024-05-10
- Published: 2025-03-20
- Earliest claimed: 2018-05-03
- Assignees: The Chinese University of Hong Kong; Grail, LLC
- Applicants: The Chinese University of Hong Kong; GRAIL, Inc.
- Inventors: Yuk-Ming Dennis Lo; Rossa Wai Kwun Chiu; Kwan Chee Chan; Peiyong Jiang; Kun Sun
- Web page: https://patentgrep.com/patent/US20250095777A1

## CPC

- G16B 30/00: ICT specially adapted for sequence analysis involving nucleotides or amino acids
- G16B 40/00: ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- C12Q 1/6881: for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- G16B 5/20: Probabilistic models
- G16B 20/10: Ploidy or copy number detection
- G16B 20/20: Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
- G16B 20/40: Population genetics; Linkage disequilibrium
- G16B 30/10: Sequence alignment; Homology search
- G16B 40/20: Supervised data analysis
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Various applications can use fragmentation patterns related of cell-free DNA, e.g., plasma DNA and serum DNA. For example, the end positions of DNA fragments can be used for various applications. The fragmentation patterns of short and long DNA molecules can be associated with different preferred DNA end positions, referred to as size-tagged preferred ends. In another example, the fragmentation patterns relating to tissue-specific open chromatin regions were analyzed. A classification of a proportional contribution of a particular tissue type can be determined in a mixture of cell-free DNA from different tissue types. Additionally, a property of a particular tissue type can be determined, e.g., whether a sequence imbalance exists in a particular region for a tissue type or whether a pathology exists for the tissue type.

## Claims

### Claim at position 1

1-30. (canceled)

### Claim 31

A method of analyzing a biological sample, including a mixture of cell-free DNA molecules from a plurality of tissue types that includes a first tissue type, to determine a classification of a proportional contribution of the first tissue type in the mixture, the method comprising:
identifying a first set of genomic positions that have a specified distance from a center of one or more tissue-specific open chromatin regions corresponding to the first tissue type;
analyzing a first plurality of cell-free DNA molecules from the biological sample of a subject, wherein analyzing a cell-free DNA molecule includes:
determining a genomic position in a reference genome corresponding to both ends of the cell-free DNA molecule; and
classifying one end as an upstream end and another end as a downstream end based on which end has a lower value for the genomic position;
determining that a first number of the first plurality of cell-free DNA molecules have an upstream end at one of the first set of genomic positions;
determining that a second number of the first plurality of cell-free DNA molecules have a downstream end at one of the first set of genomic positions;
computing a separation value between the first number and the second number; and
determining the classification of the proportional contribution of the first tissue type by comparing the separation value to one or more calibration values determined from one or more calibration samples whose proportional contributions of the first tissue type are known.

### Claim 32 (depends on 31)

The method of claim 31, wherein the one or more tissue-specific open chromatin regions include at least 500 tissue-specific open chromatin regions corresponding to the first tissue type.

### Claim 33 (depends on 31)

The method of claim 31, wherein the separation value includes a ratio and/or a difference.

### Claim 34 (depends on 31)

The method of claim 31, wherein the specified distance includes a range of distances.

### Claim 35 (depends on 34)

The method of claim 34, wherein the specified distance includes a first range of distances before the center and includes a second range of distances after the center.

### Claim 36 (depends on 35)

The method of claim 35, wherein a first contribution to the separation value is determined in a first manner for the first range, and wherein a second contribution to the separation value is determined in a second manner for the second range.

### Claim 37 (depends on 36)

The method of claim 36, wherein the separation value is determined as
OCF
=
∑
-
peak
-
bin
-
peak
+
bin
(
D
-
U
)
+
∑
peak
-
bin
peak
+
bin
(
U
-
D
)
,
wherein a peak position corresponds to an offset from the center and a bin value corresponds to a window size around the peak position, and wherein the first number is a value U at one of the genomic positions in the first set, and wherein the second number is a value D at the one of the genomic positions in the first set.

### Claim 38

A method of analyzing a biological sample, including a mixture of cell-free DNA molecules from a plurality of tissue types that includes a first tissue type, to determine a classification of whether a pathology exists for the first tissue type in the mixture, the method comprising:
identifying a first set of genomic positions that have a specified distance from a center of one or more tissue-specific open chromatin regions corresponding to the first tissue type;
analyzing a first plurality of cell-free DNA molecules from the biological sample of a subject, wherein analyzing a cell-free DNA molecule includes:
determining a genomic position in a reference genome corresponding to both ends of the cell-free DNA molecule; and
classifying one end as an upstream end and another end as a downstream end based on which end has a lower value for the genomic position;
determining that a first number of the first plurality of cell-free DNA molecules have an upstream end at one of the first set of genomic positions;
determining that a second number of the first plurality of cell-free DNA molecules have a downstream end at one of the first set of genomic positions;
computing a separation value using the first number and the second number; and
determining the classification of whether the pathology exists for the first tissue type of the subject based on a comparison of the separation value to a reference value.

### Claim 39 (depends on 38)

The method of claim 38, wherein the reference value is determined from one or more control samples that do not have the pathology.

### Claim 40 (depends on 38)

The method of claim 38, wherein the reference value is determined from one or more control samples that do have the pathology.

### Claim 41 (depends on 38)

The method of claim 38, wherein the pathology is an abnormally high fractional concentration of cell-free DNA from the first tissue type.

### Claim 42 (depends on 38)

The method of claim 38, wherein the pathology is a rejection of a transplanted organ.

### Claim 43 (depends on 38)

The method of claim 38, wherein the pathology is cancer of the first tissue type.

### Claim 44 (depends on 38)

The method of claim 38, wherein the one or more tissue-specific open chromatin regions include at least 500 tissue-specific open chromatin regions corresponding to the first tissue type.

### Claim 45 (depends on 38)

The method of claim 38, wherein the separation value includes a ratio and/or a difference.

### Claim 46 (depends on 38)

The method of claim 38, wherein the specified distance includes a range of distances.

### Claim 47 (depends on 38)

The method of claim 38, wherein the specified distance includes a first range of distances before the center and includes a second range of distances after the center.

### Claim 48 (depends on 38)

The method of claim 38, wherein a first contribution to the separation value is determined in a first manner for the first range, and wherein a second contribution to the separation value is determined in a second manner for the second range.

### Claim 49 (depends on 38)

The method of claim 38, wherein the separation value is determined as
OCF
=
∑
-
peak
-
bin
-
peak
+
bin
(
D
-
U
)
+
∑
peak
-
bin
peak
+
bin
(
U
-
D
)
,
wherein a peak position corresponds to an offset from the center and a bin value corresponds to a window size around the peak position, and wherein the first number is a value U at one of the genomic positions in the first set, and wherein the second number is a value D at the one of the genomic positions in the first set.

### Claim 50 (depends on 31)

The method of claim 31, wherein comparing the separation value to the one or more calibration values uses a calibration function fit to calibration points comprising proportional contributions of the first tissue type measured in a plurality of calibration samples and respective relative abundances determined in the plurality of calibration samples.
